Hosted on MSN17h
Adding Radioligand to Enzalutamide Boosts OS in Metastatic CRPCShe noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...
Hosted on MSN21h
Talazoparib-Enzalutamide Improves Survival in Metastatic CRPCAdding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...
If you purchased or acquired securities in ESSA Pharma between December 12, 2023 and October 31, 2024 and would like to ...
The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...
Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...
GlobalData on MSN23h
Pfizer’s Talzenna gains 14-months OS lead over mCRPC SoCResults from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.
Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...
The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second ...
From 1,085 citations identified, 48 studies with 15,368 men with mCRPC met inclusion criteria. Most studies were retrospective cohorts (n = 39) from Europe (n = 22) and North America (n = 18), with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback